ScreenerHero

RANIRani Therapeutics Holdings Inc. Class A Common Stock

NAS · US · Healthcare · Biotechnology · ranitherapeutics.com
0.8800USD+3.41%Mkt Cap: 123.66M $P/E: —

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap123.66M $
Enterprise Value57.14M $
Revenue (TTM)4.88M $
Gross Profit4.88M $
Net Income (TTM)-29.67M $
Revenue/Share0.0350 USD
Last Price0.8800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.40
PEG—
EV/EBITDA-1.77
EV/Revenue11.72
P/S24.52
P/B2.99
EPS (TTM)-0.12
EPS (Forward)-0.19
52W Range
0.440013% of range3.870
52W High3.870 USD
52W Low0.4400 USD
Profitability
Gross Margin100.00%
Oper. Margin-516.86%
EBITDA Margin0.00%
Profit Margin-1817.09%
ROE-89.89%
ROA-50.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.71M $
CapEx (TTM)88.00K $
FCF Margin-181.96%
FCF Yield-7.18%
Net Debt-49.84M $
Net Debt/EBITDA1.55
Balance Sheet
Debt/Equity0.13
Current Ratio5.31
Quick Ratio5.23
Book Value/Sh0.2850 USD
Cash/Share0.4630 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.200 USD
Upside (mean)+718.2%
Target Range5.000 USD – 11.00 USD
$5.000+718.2% to mean$11.00
# Analysts5
Ownership
Shares Out.115.42M
Float82.64M
Insiders4.91%
Institutions46.80%
Short Interest
Short Ratio8.4d
Short % Float7.73%
Short % Out.7.53%
Shares Short8.46M
Short (prev mo.)9.08M
Technical
SMA 500.7713 (+14.1%)
SMA 2001.147 (-23.3%)
Beta0.69
S&P 52W Chg18.16%
Avg Vol (30d)893.85K
Avg Vol (10d)790.05K
Technical Indicators
RSI (14)59.1
MACD0.0198
MACD Signal0.0107
MACD Hist.+0.0092
BB Upper0.8892 USD
BB Middle0.8148 USD
BB Lower0.7403 USD
BB Width18.28%
ATR (14)0.0613 USD
Vol Ratio (20d)1.01x